相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu et al.
SCIENCE (2020)
Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
Xiaoqing Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Jiajing Cai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
Barbara Melosky et al.
LUNG CANCER (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
AS1411 derivatives as carriers of G-quadruplex ligands for cervical cancer cells
Joana Figueiredo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels
S. Okamura et al.
BIOTECHNIC & HISTOCHEMISTRY (2019)
Binding affinity data of DNA aptamers for therapeutic anthracyclines from microscale thermophoresis and surface plasmon resonance spectroscopy
Stephan Sass et al.
ANALYST (2019)
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
David W. Doo et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Chunlin Li et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Selection of PD1/PD-L1 X-Aptamers
Hongyu Wang et al.
BIOCHIMIE (2018)
Aptamer Therapeutics in Cancer: Current and Future
Yoshihiro Morita et al.
CANCERS (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
The Bioactivity of D-/L-Isonucleoside- and 2′-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression
Xinmeng Fan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Marie-Cecile Mercier et al.
CANCERS (2017)
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma
Chao Liang et al.
BIOMATERIALS (2017)
Development of Phosphorothioate DNA and DNA Thioaptamers
David E. Volk et al.
BIOMEDICINES (2017)
Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma
Young Wha Koh et al.
TUMOR BIOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
Wei-Yun Lai et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Current approaches in SELEX: An update to aptamer selection technology
Mariia Darmostuk et al.
BIOTECHNOLOGY ADVANCES (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PD-L1 Inhibition With MPDL3280A for Solid Tumors
Edward Cha et al.
SEMINARS IN ONCOLOGY (2015)
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
Aaron Prodeus et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
B7 family checkpoint regulators in immune regulation and disease
Sabrina Ceeraz et al.
TRENDS IN IMMUNOLOGY (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Aptamers evolved from live cells as effective molecular probes for cancer study
Dihua Shangguan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Selection of RNA aptamers against recombinant transforming growth factor-β type III receptor displayed on cell surface
Shoji P. Ohuchi et al.
BIOCHIMIE (2006)
Mfold web server for nucleic acid folding and hybridization prediction
M Zuker
NUCLEIC ACIDS RESEARCH (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
